| Literature DB >> 35021095 |
Evan R Abt1, Thuc M Le1, Amanda M Dann2, Joseph R Capri1, Soumya Poddar1, Vincent Lok1, Luyi Li2, Keke Liang3, Amanda L Creech1, Khalid Rashid1, Woosuk Kim1, Nanping Wu2, Jing Cui4, Arthur Cho5, Hailey Rose Lee1, Ethan W Rosser1, Jason M Link6, Johannes Czernin1, Ting-Ting Wu7, Robert Damoiseaux8, David W Dawson9, Timothy R Donahue10, Caius G Radu11.
Abstract
We determine that type I interferon (IFN) response biomarkers are enriched in a subset of pancreatic ductal adenocarcinoma (PDAC) tumors; however, actionable vulnerabilities associated with IFN signaling have not been systematically defined. Integration of a phosphoproteomic analysis and a chemical genomics synergy screen reveals that IFN activates the replication stress response kinase ataxia telangiectasia and Rad3-related protein (ATR) in PDAC cells and sensitizes them to ATR inhibitors. IFN triggers cell-cycle arrest in S-phase, which is accompanied by nucleotide pool insufficiency and nucleoside efflux. In combination with IFN, ATR inhibitors induce lethal DNA damage and downregulate nucleotide biosynthesis. ATR inhibition limits the growth of PDAC tumors in which IFN signaling is driven by stimulator of interferon genes (STING). These results identify a cross talk between IFN, DNA replication stress response networks, and nucleotide metabolism while providing the rationale for targeted therapeutic interventions that leverage IFN signaling in tumors.Entities:
Keywords: STING; interferon; nucleotide metabolism; pancreas cancer; replication stress
Mesh:
Substances:
Year: 2022 PMID: 35021095 PMCID: PMC8893345 DOI: 10.1016/j.celrep.2021.110236
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423